Of note, most B-ALL diagnostic specimens have a high blast percentage, rendering the ability of a clinical assay to detect subclonal deletions non-essential; the clinical significance of subclonal IKZF1 deletions at the time of diagnosis is still an area of active exploration [82]. The gene discussed is IKZF1; the disease is acute lymphoblastic leukemia.